9/20/2023 0 Comments Konica minolta precision medicine![]() The launch of KMPMJ is the latest development in Konica Minolta’s ambitious goal of transforming personalized medicine. It will also offer diagnostic and prognostic testing services using genes, proteins, and other molecules that increase physicians’ ability to assess and treat their patients’ disease. KMPMJ will provide tools to identify and track disease-linked biomarkers 1 and related services to accelerate the development of targeted therapies. KMPMJ will be led by president Ken Masuo, a seasoned marketing executive with over 30 years of experience in the pharmaceutical industry, and will be based in Tokyo with 23 employees. The tools needed to diagnose, treat and develop new therapies Precision medicine is medical care that uses genetic and molecular profiling to optimize treatment for specific groups of patients. KMPMJ is a 100%-owned subsidiary of Konica Minolta with responsibility for marketing high-end precision medicine tools and diagnostic services in Japan. (“KMPMJ”) which will start operations on October 1, 2018. (“Konica Minolta”) (TOKYO: 4902) (ISIN: JP3300600008) today announced the launch of Konica Minolta Precision Medicine Japan, Inc. Tokyo, Japan (Septem– article source from Business Wire): Konica Minolta, Inc.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |